Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target Is $48
MT NewswiresApr 12 22:36
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
TipRanksApr 12 13:41
Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Alvotech (ALVO) and Immunocore Holdings (IMCR)
TipRanksApr 5 15:50
Catalent Analyst Ratings
BenzingaApr 4 22:24
Analysts Offer Insights on Healthcare Companies: Arbutus Biopharma (ABUS), Twist Bioscience (TWST) and Catalent (CTLT)
TipRanksMar 5 14:23
RBC Capital Reiterates Sector Perform on Catalent, Maintains $63.5 Price Target
BenzingaFeb 20 23:28
Catalent Analyst Ratings
BenzingaFeb 20 23:25
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Alnylam Pharma (ALNY) and Catalent (CTLT)
TipRanksFeb 20 20:31
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), BeiGene (BGNE) and Catalent (CTLT)
TipRanksFeb 12 21:20
Catalent (CTLT) Gets a Hold From Barclays
TipRanksFeb 12 16:46
Catalent Stock Downgraded Post Novo Nordisk Acquisition Deal
InvestingFeb 8 07:14
Analyst Maintains Hold Rating Amid Catalent's Strategic Acquisition and Complex Valuation
TipRanksFeb 7 21:35
Catalent Downgraded Post Novo Nordisk Acquisition Deal
InvestingFeb 6 20:14
Catalent Analyst Ratings
BenzingaFeb 6 18:52
Barclays Sticks to Their Hold Rating for Catalent (CTLT)
TipRanksFeb 6 14:25
Analysts' Top Healthcare Picks: Hookipa Pharma (HOOK), Catalent (CTLT)
TipRanksJan 30 20:12
RBC Raises Price Target on Catalent to $58 From $55 on Increased Confidence in Achievability of Estimates; Outperform Kept
MT NewswiresJan 30 19:56
Catalent Analyst Ratings
BenzingaJan 25 22:41
Strong Buy Rating for Catalent Backed by Growth in Biopharma Contracting and Robust Pipeline
TipRanksJan 11 14:48
Deutsche Bank Adjusts Catalent Price Target to $44 From $48, Maintains Hold Rating
MT NewswiresNov 20, 2023 23:10
No Data
No Data